Get the Stockscreener App
4.32
0.40%
0.04
After Hours:
4.32
Larimar Therapeutics Inc stock is traded at $4.32, with a volume of 882.36K.
It is up +0.40% in the last 24 hours and up +18.31% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
See More
Previous Close:
$4.36
Open:
$4.33
24h Volume:
882.36K
Relative Volume:
0.43
Market Cap:
$448.77M
Revenue:
-
Net Income/Loss:
$-166.01M
P/E Ratio:
-2.0791
EPS:
-2.0778
Net Cash Flow:
$-131.32M
1W Performance:
+9.16%
1M Performance:
+18.31%
6M Performance:
+44.47%
1Y Performance:
+9.16%
1-Day Range:
$4.30
$4.4199
1-Week Range:
$4.02
$4.465
52-Week Range:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.32 | 452.93M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Larimar Therapeutics (LRMR) to Announce Earnings on Thursday - marketbeat.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp - The Globe and Mail
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating - Moomoo
LRMR Maintained by Wedbush -- Price Target Lowered to $11.00 - GuruFocus
Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00 - MarketBeat
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Larimar Therapeutics (LRMR) Advances Nomlabofusp Submission Amid Mixed Financial Signals - GuruFocus
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary - TradingView
Larimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver Quantitative
Larimar: Q2 Earnings Snapshot - marketscreener.com
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - Yahoo Finance
Larimar Therapeutics (LRMR) Gains 3.27% as Biotech Stock Approaches Key $4.32 ResistanceAnalyst Downgrade Signals - dars.gov.et
SummitTX Capital L.P. Invests $1.71 Million in Larimar Therapeutics, Inc. $LRMR - MarketBeat
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
LRMR|Larimar Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
TradingKey - TradingKey
Larimar Therapeutics Market Sentiment - Benzinga España
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR - tradingview.com
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
LRMR|Larimar Therapeutics Inc|Price:4.000|Chg%:-0.010 - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
Larimar Therapeutics Files First Module of BLA for Nomlabofusp in Friedreich's Ataxia TreatmentNew Analyst Coverage - dars.gov.et
Larimar Therapeutics Initiates BLA Submission for Nomlabofusp in Friedreich’s AtaxiaProfit Guidance Range - dars.gov.et
Larimar Therapeutics Files Initial BLA Module for Nomlabofusp in Friedreich's AtaxiaPre-Announcement Alert - dars.gov.et
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
Price to sales forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics - Moomoo
Larimar Therapeutics stock jumps on insider purchase By Investing.com - Investing.com South Africa
Larimar Therapeutics stock jumps on insider purchase - Investing.com
Larimar Therapeutics director buys $166,890 in company stock - Investing.com UK
Enterprise value to revenue forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 - TradingView
Larimar Therapeutics director buys $166,890 in company stock By Investing.com - Investing.com South Africa
Form 4 Larimar Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Larimar Therapeutics (LRMR) director purchases 50,000 common shares - Stock Titan
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Larimar Therapeutics Inc Stock (LRMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flynn James E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000,000 |
25,000,000 |
10,622,957 |
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):